The biologically inactive vitamin D 3 (cholecalciferol) is produced in the skin after solar UVB exposure.

Trial registrationĬ, NCT01723852, registration date. The results enable institution of evidence-based guidelines for vitamin D supplementation in infancy. The study enables evaluation of short and long term effects of supplemental vitamin D on growth, immune functions and skeletal and developmental parameters in infants, and the effects of genetic factors therein. Both groups are assessed at 6 months of age for calcium homeostasis, and at 12 and 24 months of age for parameters associated with bone strength, growth, developmental milestones, infections, immunity, atopy-related diseases, and genetic factors involved in these functions. Participants, recruited at Helsinki Maternity Hospital, are randomised to receive daily either 10 μg (400 IU) or 30 μg (1 200 IU) of vitamin D3 supplementation. VIDI, a randomised controlled double-blinded single-centre intervention study is conducted in infants from the age of 2 weeks to 24 months. Genetic regulation of mineral homeostasis The VIDI trial performed in Finland is the first large randomised controlled study for evaluation of the effects of different vitamin D supplemental doses in infancy on: It remains unclear whether the recommended doses are sufficient for the wide array of other effects of vitamin D.

Many countries apply vitamin D supplementation strategies in infants, but the guidelines are not based on scientific evidence and aim at prevention of rickets.

Additionally, it is considered a requirement for a multitude of processes associated with, for example, the development of immunity. Vitamin D is important for bone mass accrual during growth.

Download vitamin d for infants